PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease

Cancer Cell

Volumn 3, Issue 5, 2003, Pages 459-469

  Cools, Jan ^a,b   Stover, Elizabeth H ^a   Boulton, Christina L ^a   Gotlib, Jason ^c   Legare, Robert D ^d   Amaral, Sonia M ^a   Curley, David P ^a   Duclos, Nicole ^a   Rowan, Rebecca ^a   Kutok, Jeffery L ^a   Lee, Benjamin H ^a   Williams, Ifor R ^e   Coutre, Steven E ^c   Stone, Richard M ^f   Deangelo, Daniel J ^f   Marynen, Peter ^b   Manley, Paul W ^g   Meyer, Thomas ^g   Fabbro, Doriano ^g   Neuberg, Donna ^f   Weisberg, Ellen ^f   Griffin, James D ^f   Gilliland, D Gary ^a,f   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MIDOSTAURIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; DRUG DERIVATIVE; FIP1L1 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STAUROSPORINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; DRUG EFFICACY; EMBRYO; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; BONE MARROW; CELL LINE; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG RESISTANCE; GENE VECTOR; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MUTATION; PATHOLOGY; RECURRENT DISEASE; RETROVIRUS; SERODIAGNOSIS; SPLEEN; TIME; WESTERN BLOTTING;

ANIMALIA; MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL LINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FUSION PROTEINS, BCR-ABL; GENETIC VECTORS; HUMANS; IMMUNOPHENOTYPING; MICE; MODELS, GENETIC; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; MYELOPROLIFERATIVE DISORDERS; PIPERAZINES; PRECIPITIN TESTS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECURRENCE; RETROVIRIDAE; SPLEEN; STAUROSPORINE; TIME FACTORS;

EID: 0142119964     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00108-9     Document Type: Article

References (43)

1. Andrejauskas-Buchdunger E., Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res. 52:1992;5353-5358.
2. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E.et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347:2002;481-487.
3. Ault P., Cortes J., Koller C., Kaled E.S., Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk. Res. 26:2002;881-884.
4. Baxter E.J., Hochhaus A., Bolufer P., Reiter A., Fernandez J.M., Senent L., Cervera J., Moscardo F., Sanz M.A., Cross N.C. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum. Mol. Genet. 11:2002;1391-1397.
5. Baxter E.J., Kulkarni S., Vizmanos J.L., Jaju R., Martinelli G., Testoni N., Hughes G., Salamanchuk Z., Calasanz M.J., Lahortiga I.et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br. J. Haematol. 120:2003;251-256.
6. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:2002;493-502.
7. Chusid M.J., Dale D.C., West B.C., Wolff S.M. The hypereosinophilic syndrome. analysis of fourteen cases with review of the literature Medicine (Baltimore). 54:1975;1-27.
8. Cohen P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1:2002;309-315.
9. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D.et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:2003;1201-1214.
10. Cortes J., Ault P., Koller C., Thomas D., Ferrajoli A., Wierda W., Rios M.B., Letvak L., Kaled E.S., Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. in press. 2003;. Published online February 20, 2003. DOI 10.1182/blood-2003-01-0081.
11. Daley G.Q., Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/ abl protein. Proc. Natl. Acad. Sci. USA. 85:1988;9312-9316.
12. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
13. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480.
14. Druker B.J. Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. 40:2003;50-58.
15. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001;1038-1042. a.
16. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037. b.
17. Fabbro D., Buchdunger E., Wood J., Mestan J., Hofmann F., Ferrari S., Mett H., O'Reilly T., Meyer T. Inhibitors of protein kinases. CGP 41251, a protein kinase inhibitor with potential as an anticancer agent Pharmacol. Ther. 82:1999;293-301.
18. Fabbro D., Ruetz S., Bodis S., Pruschy M., Csermak K., Man A., Campochiaro P., Wood J., O'Reilly T., Meyer T. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 15:2000;17-28.
19. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., Mestan J., O'Reilly T., Traxler P., Chaudhuri B.et al. Protein kinases as targets for anticancer agents. from inhibitors to useful drugs Pharmacol. Ther. 93:2002;79-98.
20. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 359:2002;1577-1578.
21. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307-316.
22. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
23. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A.et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710.
24. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M.et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580.
25. Kelly L.M., Liu Q., Kutok J.L., Williams I.R., Boulton C.L., Gilliland D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 99:2002;310-318. a.
26. Kelly L.M., Yu J.C., Boulton C.L., Apatira M., Li J., Sullivan C.M., Williams I., Amaral S.M., Curley D.P., Duclos N.et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1:2002;421-432. b.
27. Lamers M.B., Antson A.A., Hubbard R.E., Scott R.K., Williams D.H. Structure of the protein tyrosine kinase domain of C-terminal src kinase (CSK) in complex with staurosporine. J. Mol. Biol. 285:1999;713-725.
28. La Rosee P., Corbin A.S., Stoffregen E.P., Deininger M.W., Druker B.J. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62:2002;7149-7153.
29. Longley B.J., Tyrrell L., Lu S.Z., Ma Y.S., Langley K., Ding T.G., Duffy T., Jacobs P., Tang L.H., Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis. establishment of clonality in a human mast cell neoplasm Nat. Genet. 12:1996;312-314.
30. MacDonald T.J., Brown K.M., LaFleur B., Peterson K., Lawlor C., Chen Y., Packer R.J., Cogen P., Stephan D.A. Expression profiling of medulloblastoma. PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease Nat. Genet. 29:2001;143-152.
31. Magnusson M.K., Meade K.E., Brown K.E., Arthur D.C., Krueger L.A., Barrett A.J., Dunbar C.E. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood. 98:2001;2518-2525.
32. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., Metcalfe D.D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA. 92:1995;10560-10564.
33. Pardanani A.D., Reeder T.L., Porrata L.F., Li C.Y., Tazelaar H.D., Baxter E.J., Witzig T.E., Cross N.C., Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 101:2002;3391-3397.
34. Propper D.J., McDonald A.C., Man A., Thavasu P., Balkwill F., Braybrooke J.P., Caponigro F., Graf P., Dutreix C., Blackie R.et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. 19:2001;1485-1492.
35. Ross T.S., Bernard O.A., Berger R., Gilliland D.G. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 91:1998;4419-4426.
36. Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., Peeters P., Van Rompaey L., Van Etten R.A., Ilaria R. Jr. et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17:1998;5321-5333.
37. Schwaller J., Anastasiadou E., Cain D., Kutok J., Wojiski S., Williams I.R., LaStarza R., Crescenzi B., Sternberg D.W., Andreasson P.et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood. 97:2001;3910-3918.
38. Shah N., Nicoll J., Nagar B., Gorre M., Paquette R., Kuriyan J., Sawyers C. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117-125.
39. Stone R.M., Klimek V., DeAngelo D.J., Nimer S., Estey E., Galinsky I., Neuberg D., Yap A., Fox E.A., Gilliland D.G., Griffin J. PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML). a phase II clinical trial Blood. 100:2003;86a.
40. Toledo L.M., Lydon N.B. Structures of staurosporine bound to CDK2 and cAPK - new tools for structure-based design of protein kinase inhibitors. Structure. 5:1997;1551-1556.
41. Tomasson M.H., Sternberg D.W., Williams I.R., Carroll M., Cain D., Aster J.C., Ilaria R.L. Jr., Van Etten R.A., Gilliland D.G. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J. Clin. Invest. 105:2000;423-432.
42. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T., Gilliland D.G., Griffin J.D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443.
43. Weller P.F., Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood. 83:1994;2759-2779.